Skip to the content
ClearNote Health logologo darklogo light
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Search
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Home2024October
Event

Society for Immunotherapy of Cancer | Nov 6 – 10, 2024

cnhnewcorpdev
October 8, 2024
Event

AACR Special Conference on Liquid Biopsy | November 12 -16, 2024

cnhnewcorpdev
October 7, 2024
Event

CGA-IGC – Hereditary Gastrointestinal Cancer | Nov 14-16, 2024

cnhnewcorpdev
October 6, 2024
Event

ISPOR Europe | Nov 17-20, 2024

cnhnewcorpdev
October 5, 2024

ClearNote Health to Present Industry-Leading Early Detection Data for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026

ClearNote Health
May 8, 2026

ClearNote Health to Showcase Industry-Leading Early Detection Performance of the Avantect® Pancreatic Cancer Test at AACR Annual Meeting 2026

cnhnewcorpdev
April 15, 2026

Follow us

Company

  • About Us
  • Leadership Team
  • Careers
  • Get In Touch

Information

  • Billing Rights & Protections
  • Cookie Policy
  • Privacy Policy
  • Terms of Use

©2026 ClearNote Health, All Rights Reserved.
Avantect and Virtuoso are trademarks of ClearNote Health. Other trademarks are the property of their respective owners.

Important Information
The Virtuoso platform is for research use only. Not for use in diagnostic procedures. The Avantect Pancreatic and Ovarian Cancers Tests are early detection tests. The tests do not establish a diagnosis of pancreatic cancer or ovarian cancer, respectively, and results should be considered in the context of other clinical criteria. Cancer statistics quoted on this website are taken from the CDC and SEER websites, 2025 data.

Back to top Drag
w